ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMGastos comerciales, generales y administrativos148.1 M121.8 M124.8 M106.8 M103 M456.4 MInvestigación y desarrollo——————Beneficio operativo-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-872.6 MTotal de ingresos no operativos2.5 M-5.6 M-17.1 M2.5 M1.1 M-19.1 MGastos por intereses, netos de intereses capitalizados——————Ingresos no operativos, una vez deducidos los gastos por intereses-3.7 M-5.6 M-19.9 M-2.6 M1.1 M-27 MIngresos/gastos extraordinarios6.2 M02.8 M5.1 M07.9 MBeneficio antes de impuestos-74.9 M-548 M-370.7 M-28.7 M-35.6 M-983 MParticipación en los beneficios——————Impuestos-1 M14.9 M4.2 M-12.8 M-3.1 M3.2 MParticipación minoritaria——————Otros ingresos/gastos después de impuestos-4.6 M-300 K-2 M100 K-2.3 M-4.5 MBeneficio neto antes de actividades interrumpidas-73.9 M-562.9 M-374.9 M-15.9 M-32.5 M-986.2 MOperaciones suspendidas12.7 M00000Beneficio neto-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-986.2 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-61.2 M-562.9 M-374.9 M-15.9 M-32.5 M-986.2 MBeneficio básico por acción-0.68-6.25-4.14-0.17-0.25-10.81Beneficio por acción diluido-0.68-6.25-4.14-0.17-0.25-10.81Número medio de acciones ordinarias89.5 M—————Acciones diluidas89.5 M—————EBITDA-34.8 M-500.6 M-310.7 M11 M5.7 M-794.6 MEBIT-55.6 M-520.1 M-330.3 M-8.6 M-13.6 M-872.6 MCosto de los ingresos556.1 M534.8 M576.8 M578.6 M529.4 M2.22 BOtros costes de producción556.1 M534.8 M576.8 M578.6 M529.4 M2.22 BAmortización y depreciación (flujo de caja)20.8 M19.5 M19.6 M19.6 M19.3 M78 M
Fortrea Holdings Inc
Fortrea Holdings Inc. is an American contract research organization organized in Delaware and headquartered in Durham, North Carolina with operations in 90 countries. Its customers are primarily in the pharmaceutical, biotechnology, and medical device industries.
Its primary business is handling all aspects of clinical trials including phase I through IV clinical trial management, clinical pharmacology, and post-approval services. It handles regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. It focuses on oncology, central nervous system and neurodegenerative, rare diseases, and cell and gene therapies. In the five years ending in 2023, it conducted more than 5,850 clinical trials involving over 1 million subjects. It also conducted over 600 studies for medical device companies.
The company is one of the largest participants in the international primate trade and has been criticized for its animal testing practices, most specifically animal testing on non-human primates.